Currently marketed as Neo-Contact, the drugs include two types of aminomethylamine tablets or compound pseudoephedrine hydrochloride extended-release capsules, both of which are not recommended for use during breastfeeding, and it is recommended that breastfeeding be resumed after at least 72 hours, if necessary, after consultation with a physician. According to the drug’s instructions for use, aminomethylamine tablets are contraindicated for use in breastfeeding women, and cotrimoxazole pseudoephedrine hydrochloride extended-release capsules lack information on use during breastfeeding and are not recommended for use in breastfeeding women or for discontinuing breastfeeding. Both drugs contain pseudoephedrine and chlorpheniramine maleate, both of which are secreted through breast milk and can affect the infant’s nervous system, potentially causing adverse effects on the infant. Meanwhile, chlorpheniramine maleate can inhibit lactation and affect the amount of milk produced. Therefore, it is not recommended to use this kind of drug during breastfeeding, and it is recommended to wait at least 72 hours after taking the drug to wait for the drug to be excreted before breastfeeding, and it is recommended to strictly follow the doctor’s instructions for the use of drugs during breastfeeding.